Reference Values for N-terminal Pro-brain Natriuretic Peptide in Premature Infants During Their First Weeks of Life

Overview

Journal Eur J Pediatr

Specialty Pediatrics

Date 2020 Nov 3

PMID 33141298

Citations 10

Authors

Agnes-Sophie Fritz

Titus Keller

Angela Kribs

Christoph Hunseler

Affiliations

Soon will be listed here.

Abstract

The aim of our study was to observe the temporal distribution of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in premature infants of ≤ 31 weeks of gestational age (GA) during the first weeks of life. NT-proBNP values of 118 preterm infants born ≤ 31 weeks GA were determined during the first week of life, after 4 ± 1 weeks of life, and at a corrected GA of 36 ± 2 weeks. Infants were divided into two groups: those without relevant complications and those with complications related to prematurity. NT-proBNP values of infants without complications define our exploratory reference values. The Median NT-proBNP level of these infants was 1896 ng/l (n = 27, interquartile range (IQR): 1277-5200) during the first week of life, 463 ng/l (n = 26, IQR: 364-704) at 4 ± 1 weeks of life, and 824 ng/l (n = 33, IQR: 714-1233) at a corrected GA of 36 ± 2 weeks. Infants born < 28 + 0 weeks GA had significantly higher NT-proBNP values (n = 9, median: 5200, IQR: 1750-8972) than infants born ≥ 28 + 0-31 weeks GA (n = 18, median: 1528, IQR: 838-3052; p = 0.017). Growth restriction or PDA status could not account for the difference in NT-proBNP values between GA groups.Conclusions: The results of our observational and cross-sectional study describe exploratory reference values for NT-proBNP levels in preterm infants of ≤ 31 weeks GA according to postnatal age. NT-proBNP levels during the first week of life are high and widely distributed in preterm infants and decrease subsequently to reach a distinctly lower and stable plateau at around 1 month of life. Our results suggest an influence of GA on NT-proBNP values in the first week of life. What is Known: • Several complications related to prematurity, e.g., hemodynamically significant PDA, pulmonary hypertension, bronchopulmonary dysplasia, and retinopathy of prematurity, have been associated with a temporary rise in NT-proBNP values in preterm infants during their first weeks of life. What is New: • This observational study provides reference values for NT-proBNP levels of very and extremely preterm infants during their first weeks of life. • In premature infants without complications, NT-proBNP values during their first week of life depend on gestational age at birth.

Citing Articles

NT-proBNP, to be or not to be a BPD biomarker?.

Danhaive O, Hocq C Pediatr Res. 2024; .

PMID: 39482496 DOI: 10.1038/s41390-024-03681-8.

Bronchopulmonary dysplasia - associated pulmonary hypertension: An updated review.

El-Saie A, Varghese N, Webb M, Villafranco N, Gandhi B, Guaman M Semin Perinatol. 2023; 47(6):151817.

PMID: 37783579 PMC: 10843293. DOI: 10.1016/j.semperi.2023.151817.

NT-PROBNP as a screening tool for low-risk patent ductus arteriousus: a follow-up validation study.

Lopez-Blanco G, Oulego-Erroz I, Pou-Blazquez A, Medina-Guerrero C, Rodriguez-Blanco S, Alonso-Quintela P Eur J Pediatr. 2023; 182(12):5465-5471.

PMID: 37773295 DOI: 10.1007/s00431-023-05213-8.

N-Terminal Pro-B Type Natriuretic Peptide as a Predictive Biomarker of Bronchopulmonary Dysplasia or Death Due to Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Meta-Analysis.

Rodolaki K, Pergialiotis V, Sapantzoglou I, Theodora M, Antsaklis P, Pappa K J Pers Med. 2023; 13(9).

PMID: 37763055 PMC: 10532602. DOI: 10.3390/jpm13091287.

The diagnostic value of n-terminal probrain natriuretic peptides to differentiate neonatal pneumoniae and transient tachypnea of the newborn.

Arslan Z, Alan S, Aliefendioglu D Turk J Med Sci. 2023; 53(2):486-494.

PMID: 37476880 PMC: 10387986. DOI: 10.55730/1300-0144.5608.

References

Levin E, Gardner D, Samson W . Natriuretic peptides. N Engl J Med. 1998; 339(5):321-8. DOI: 10.1056/NEJM199807303390507. View

Vanderheyden M, Bartunek J, Goethals M . Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail. 2004; 6(3):261-8. DOI: 10.1016/j.ejheart.2004.01.004. View

Tagore R, Ling L, Yang H, Daw H, Chan Y, Sethi S . Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3(6):1644-51. PMC: 2572269. DOI: 10.2215/CJN.00850208. View

Harris S, More K, Dixon B, Troughton R, Pemberton C, Horwood J . Factors affecting N-terminal pro-B-type natriuretic peptide levels in preterm infants and use in determination of haemodynamic significance of patent ductus arteriosus. Eur J Pediatr. 2018; 177(4):521-532. DOI: 10.1007/s00431-018-3089-y. View

Letshwiti J, Sirc J, OKelly R, Miletin J . Serial N-terminal pro-brain natriuretic peptide measurement as a predictor of significant patent ductus arteriosus in preterm infants beyond the first week of life. Eur J Pediatr. 2014; 173(11):1491-6. DOI: 10.1007/s00431-014-2350-2. View

Kalra V, DeBari V, Zauk A, Kataria P, Myridakis D, Kiblawi F . Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus. Ann Clin Lab Sci. 2011; 41(2):131-7. View

Mendez-Abad P, Zafra-Rodriguez P, Lubian-Lopez S, Benavente-Fernandez I . NTproBNP is a useful early biomarker of bronchopulmonary dysplasia in very low birth weight infants. Eur J Pediatr. 2019; 178(5):755-761. DOI: 10.1007/s00431-019-03347-2. View

Joseph L, Nir A, Hammerman C, Goldberg S, Ben Shalom E, Picard E . N-terminal pro-B-type natriuretic peptide as a marker of bronchopulmonary dysplasia in premature infants. Am J Perinatol. 2009; 27(5):381-6. DOI: 10.1055/s-0029-1243312. View

Kalra V, Aggarwal S, Arora P, Natarajan G . B-type natriuretic peptide levels in preterm neonates with bronchopulmonary dysplasia: a marker of severity?. Pediatr Pulmonol. 2013; 49(11):1106-11. DOI: 10.1002/ppul.22942. View

10.

Montaner A, Pinillos R, Galve Z, Boix H, Ruiz de la Cuesta C, Jimenez L . Brain Natriuretic Propeptide as an Early Marker of Bronchopulmonary Dysplasia or Death in the Preterm Newborn. Klin Padiatr. 2017; 229(4):223-228. DOI: 10.1055/s-0043-111597. View

11.

Ten Kate C, Tibboel D, Kraemer U . B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review. Eur J Pediatr. 2015; 174(10):1267-75. DOI: 10.1007/s00431-015-2619-0. View

12.

Shah N, Natarajan G, Aggarwal S . B-type natriuretic peptide: biomarker of persistent pulmonary hypertension of the newborn?. Am J Perinatol. 2015; 32(11):1045-9. DOI: 10.1055/s-0035-1548540. View

13.

Konig K, Guy K, Walsh G, Drew S, Barfield C . Association of BNP, NTproBNP, and early postnatal pulmonary hypertension in very preterm infants. Pediatr Pulmonol. 2016; 51(8):820-4. DOI: 10.1002/ppul.23391. View

14.

Vijlbrief D, Benders M, Kemperman H, van Bel F, de Vries W . B-type natriuretic peptide and rebound during treatment for persistent pulmonary hypertension. J Pediatr. 2011; 160(1):111-5.e1. DOI: 10.1016/j.jpeds.2011.06.038. View

15.

Montgomery A, Bazzy-Asaad A, Asnes J, Bizzarro M, Ehrenkranz R, Weismann C . Biochemical Screening for Pulmonary Hypertension in Preterm Infants with Bronchopulmonary Dysplasia. Neonatology. 2016; 109(3):190-4. DOI: 10.1159/000442043. View

16.

Buhrer C, Erdeve O, van Kaam A, Berger A, Lechner E, Bar-Oz B . N-terminal B-type natriuretic peptide urinary concentrations and retinopathy of prematurity. Pediatr Res. 2017; 82(6):958-963. DOI: 10.1038/pr.2017.179. View

17.

Cantinotti M, Giovannini S, Murzi B, Clerico A . Diagnostic, prognostic and therapeutic relevance of B-type natriuretic hormone and related peptides in children with congenital heart diseases. Clin Chem Lab Med. 2011; 49(4):567-80. DOI: 10.1515/CCLM.2011.106. View

18.

Eindhoven J, van den Bosch A, Boersma E, Roos-Hesselink J . The usefulness of brain natriuretic peptide in simple congenital heart disease - a systematic review. Cardiol Young. 2012; 23(3):315-24. DOI: 10.1017/S1047951112001205. View

19.

Lee J, Polin R . Treatment and prevention of necrotizing enterocolitis. Semin Neonatol. 2004; 8(6):449-59. PMC: 7128229. DOI: 10.1016/S1084-2756(03)00123-4. View

20.

De Vecchis R, Ariano C . Measuring B-Type Natriuretic Peptide From Capillary Blood or Venous Sample: Is It the Same?. Cardiol Res. 2017; 7(2):51-58. PMC: 5295542. DOI: 10.14740/cr468e. View